Endocrinology

Men, individuals with 15 years of type 2 diabetes, and those older than 55 years old had the greatest absolute risk reduction.

Our latest case report from Brady Pregerson, MD, features a middle-aged woman brought to the emergency department by paramedics as a field-activated ST-elevation MI. Check out the EKG and see if you can determine the correct diagnosis.

A retrospective analysis of matched cohorts has led investigators to suggest bariatric surgery should be viewed as a first-line treatment for the management of obesity in patients with type 2 diabetes.

April's month in review features stories related to new diabetes medications, stem cells, disparities in care of women, and how exposure to endocrine-disrupting chemicals in pregnancy can impact mental health following delivery. Check back in during the last weekend of each month for the next Endocrine Month in Review.

Data from a cohort of more than 50k French women indicates the presence of migraine prior to entering menopause was associated with a nearly 30% greater risk of developing hypertension.

An analysis of more than 400 women with peripartum cardiomyopathy is providing insight into a group of genetic variants that could help identify patients who are genetically predisposed to the rare cardiovascular condition.

The largest study of its kind is providing insight related to changes in blood pressure seen among transgender patients initiating gender-affirming hormone therapy.

The approval, which was awarded to Mayne Pharma, makes NEXTSTELLIS the first and only contraceptive pill containing E4, a natural occurring estrogen to receive approval from the FDA.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

An analysis of nearly 3k women from a single county in Minnesota suggests pregnancy was associated with an increased risk of kidney stones and results provide insight into when this apparent risk peaks and subsides.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

An analysis of body weight and PBAC score from 121 women in Scotland suggests the presence of obesity could be linked to heavier menstrual bleeding and cause delays in womb lining repair.

Our latest case report from Dr. Brady Pregerson features a man in his 40s presenting with shortness of breath and worsening leg edema. Can you determine the correct diagnosis?

While data indicates care has improved, a retrospective study from investigators at Columbia University suggests differences in rates of failure to rescue from severe maternal morbidity were a major contributor to the disparity in excess maternal mortality seen among Black women.

Dr. Nisha Parikh provides additional insight into the AHA's latest scientific statement, which highlights the need for greater attention and emphasis on the impact of adverse pregnancy outcomes on cardiovascular risk in women.

An analysis of nearly 150 pregnant women presenting NY-based medical centers suggests prenatal exposure to endocrine-disrupting chemicals in plastics could increase odds of developing postpartum depression.

The study represents the first to examine a PPD connection to allopregnanolone.

A study from Canada is calling for additional attention to paid to the screening, diagnosis, and treatment of primary aldosteronism in adult patients.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

A phase 2 trial examining the effects of daily semaglutide over a 72-week period suggests the GLP1-RA could help patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) achieve NASH resolution.

An analysis of data from the Marketscan database suggests undergoing bariatric surgery in severely obese patients with NAFLD could reduce risk of cancer among these patients.

An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.

A single-center study presented at ENDO 2021 suggests more than half of the patients with thyroid eye disease patients treated with teprotumumab (Tepezza) developed otologic symptoms.

Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.

The therapy could offer a therapeutic option with a better safety profile, investigators said.